Effect of antioxidants on mitochondrial function in HIV-1-related lipoatrophy: A pilot study

AIDS Research and Human Retroviruses

Volumn 26, Issue 11, 2010, Pages 1207-1214

  Milazzo, Laura ^a   Menzaghi, Barbara ^a   Caramma, Ilaria ^a   Nasi, Milena ^b   Sangaletti, Ornella ^a   Cesari, Miriam ^a   Poma, Barbara Zanone ^a   Cossarizza, Andrea ^b   Antinori, Spinello ^a   Galli, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACETYLCARNITINE; ACETYLCYSTEINE; ANTIOXIDANT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CARBON 13; CARBON DIOXIDE; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS LAMIVUDINE; FOSAMPRENAVIR; GLUCOSE; LIPID; LOPINAVIR PLUS RITONAVIR; METHIONINE; MITOCHONDRIAL DNA; NEVIRAPINE; SAQUINAVIR; TENOFOVIR; THIOCTIC ACID; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BREATH ANALYSIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EXCRETION; EXHALATION; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPID ANALYSIS; LIPID METABOLISM; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; PILOT STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; T LYMPHOCYTE;

ABSORPTIOMETRY, PHOTON; ACETYLCARNITINE; ADULT; ANTIOXIDANTS; BODY COMPOSITION; BREATH TESTS; CARBOHYDRATE METABOLISM; CARBON ISOTOPES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GLUCOSE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPID METABOLISM; MALE; METHIONINE; MIDDLE AGED; MITOCHONDRIA; PILOT PROJECTS; THIOCTIC ACID;

EID: 78649297869     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0024     Document Type: Article

References (33)

1. Lewis W: Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy. Antivir Ther 2005;10:M13-27.
2. Behrens GM. Treatment options for lipodystrophy in HIV-positive patients. Export Opin Pharmacother 2008;9:39-52.
3. Miró O, Gómez M, Pedrol E, Cardellach F, Nunes V, and Casademont J: Respiratory chain dysfunction associated with multiple mitochondrial DNA deletions in antiretroviral therapy-related lipodystrophy. AIDS 2000;14:1855-1857.
4. Gerschenson M, Shiramizu B, LiButti DE, and Shikuma CM: Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther 2005;10:M83-89.
5. Kohler JJ and Lewis W: A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 2007;48:166-172.
6. White EL, Parker WB, Macy LJ, et al.: Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochem Biophys Res Commun 1989;161:393-398.
7. Barile M, Valenti D, Hobbs GA, et al.: Mechanisms of toxicity of 3'-azido-3'-deoxythymidine. Its interaction with adenylate kinase. Biochem Pharmacol 1994;48:1405-1412.
8. Valenti D, Atlante A, Barile M, and Passarella S: Inhibition of phosphate transport in rat heart mitochondria by 3'-azido-3'-deoxythymidine due to stimulation of superoxide anion mitochondrial production. Biochem Pharmacol 2002;64:201-206.
9. Negredo E, Miró O, Rodríguez-Santiago B, et al.: Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin Infect Dis 2009;49:892-900.
10. Tebas P, Zhang J, Yarasheski K, et al.: Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr 2007;45:193-200.
11. Valantin MA, Lanoy E, Bentata M, et al.: Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. HIV Med 2008;9:625-635.
12. Shen W, Liu K, Tian C, et al.: R-alpha-lipoic acid and acetyl-L-carnitine complementarily promote mitochondrial biogenesis in murine 3T3-L1 adipocytes. Diabetologia 2008;51:165-174.
13. Calvani M: Acetyl-L-carnitine. Altern Med Rev 1999;4:438-441.
14. Famularo G, Moretti S, Marcellini S, et al.: Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 1997;11:185-190.
15. Hart AM, Wilson AD, Montovani C, et al.: Acetyl-l-carnitine: A pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 2004;18:1549-1560.
16. Gualandri W, Gualandri L, Demartini G, et al.: Redox balance in patients with Down's syndrome before and after dietary supplementation with a-lipoic acid and l-cysteine. Int J Clin Pharmacol Res 2003;13:23-30.
17. Walgren JL, Amani Z, McMillan JM, Locher M, and Buse MG: Effect of R (+) alpha-lipoic acid on pyruvate metabolism and fatty acid oxidation in rat hepatocytes. Metabolism 2004;53:165-173.
18. Milazzo L, Piazza M, Sangaletti O, et al.: [13C]-Methionine breath test: A novel method to detect antiretroviral drugrelated mitochondrial toxicity. J Antimicrob Chemother 2005;55:84-89.
19. Lohman M, Tallroth K, Kettunen JA, and Marttinen MT: Reproducibility of dual-energy x-ray absorptiometry total and regional body composition measurements using different scanning positions and definitions of regions. Metabolism 2009;58:1663-1668.
20. Crisp M, Starkey KJ, Lane C, Ham J, and Ludgate M: Adipogenesis in thyroid eye disease. Invest Ophthalmol Vis Sci 2000;41:3249-3255.
21. Mussini C, Pinti M, Bugarini R, et al.: Effect of CD4-monitored treatment interruption on mitochondrial DNA content in HIV-infected patients: A prospective study. AIDS 2005;19:1627-1633.
22. Banasch M, Goetze O, Hollborn I, et al.: 13C-methionine breath test detects distinct hepatic mitochondrial dysfunction in HIV-infected patients with normal serum lactate. J Acquir Immune Defic Syndr 2005;40:149-154.
23. Jaruga P, Jaruga B, Gackowski D, et al.: Supplementation with antioxidant vitamins prevents oxidative modification of DNA in lymphocytes of HIV-infected patients. Free Radic Biol Med 2002;32:414-420.
24. Brown TT. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab 2008;93:2937-2945.
25. Carr A, Workman C, Carey D, et al.: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, doubleblind, placebo-controlled trial. Lancet 2004;363:429-438.
26. Day L, Shikuma C, and Gerschenson M: Acetyl-L-carnitine for the treatment of HIV lipoatrophy. Ann NY Acad Sci 2004;1033:139-146.
27. Benedini S, Perseghin G, Terruzzi I, et al.: Effect of L-acetylcarnitine on body composition in HIV-related lipodystrophy. Horm Metab Res 2009;41:840-845.
28. Loignon M and Toma E: L-Carnitine for the treatment of highly active antiretroviral therapy-related hypertriglyceridemia in HIV-infected adults. AIDS 2001;15:1194-1195.
29. Mussini C, Pinti M, Bugarini R, et al.: Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: A prospective study. AIDS 2005;19:1627-1633.
30. McComsey G, Southwell H, Gripshover B, Salata R, and Valdez H: Effect of antioxidants on glucose metabolism and plasma lipids in HIV-infected subjects with lipoatrophy. J Acquir Immune Defic Syndr 2003;33:605-607.
31. Falutz J. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Pract Endocrinol Metab 2007;3:651-661.
32. Duong M, Petit JM, Piroth L, et al.: Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:245-250.
33. Palacios R, Merchante N, Macias J, et al.: Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther 2006;11:529-535.